These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38318719)

  • 1. Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
    Klencke BJ; Donahue R; Gorsh B; Ellis C; Kawashima J; Strouse B
    Future Oncol; 2024 Apr; 20(11):703-715. PubMed ID: 38318719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
    Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U
    Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Momelotinib for the treatment of myelofibrosis with anemia.
    Tremblay D; Mesa R
    Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Jul; 65(7):965-977. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
    Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
    Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
    Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
    Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
    Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Oh S; Klencke BJ; Yu J; Donahue R; Kawashima J; Mesa R
    Lancet Haematol; 2023 Sep; 10(9):e735-e746. PubMed ID: 37517413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].
    Kosugi H
    Rinsho Ketsueki; 2024; 65(8):798-809. PubMed ID: 39231711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
    Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
    Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
    Vachhani P; Verstovsek S; Bose P
    Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
    Gangat N; Begna KH; Al-Kali A; Hogan W; Litzow M; Pardanani A; Tefferi A
    Am J Hematol; 2023 Feb; 98(2):282-289. PubMed ID: 36349465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.
    Bose P; Kuykendall AT; Miller C; Kurtin S; Farina K; Harting DM; Mascarenhas JO; Mesa RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1091-1100. PubMed ID: 37163478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
    Winton EF; Kota V
    Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
    Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
    Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
    Oh ST; Mesa RA; Harrison CN; Bose P; Gerds AT; Gupta V; Scott BL; Kiladjian JJ; Lucchesi A; Kong T; Buckley SA; Tyavanagimatt S; Harder BG; Roman-Torres K; Smith J; Craig AR; Mascarenhas J; Verstovsek S
    Blood Adv; 2023 Oct; 7(19):5835-5842. PubMed ID: 37552106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
    Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
    Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
    Stein BL
    Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational Janus kinase inhibitors in development for myelofibrosis.
    Bose P; Abou Zahr A; Verstovsek S
    Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.